Assertio (ASRT)
(Delayed Data from NSDQ)
$0.99 USD
+0.06 (6.44%)
Updated May 31, 2024 04:00 PM ET
After-Market: $0.99 0.00 (-0.48%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ASRT 0.99 +0.06(6.44%)
Will ASRT be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for ASRT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ASRT
Assertio (ASRT) Stock Plunges 65% in 3 Months: Here's Why
Assertio (ASRT) Shares Fall as Dan Peisert Steps Down as CEO
ASRT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is the Options Market Predicting a Spike in Assertio (ASRT) Stock?
Is the Options Market Predicting a Spike in Assertio (ASRT) Stock?
Assertio (ASRT) Q2 Earnings Miss Estimates
Other News for ASRT
Assertio Therapeutics’ Governance and Shareholder Decisions Update
Nektar, Verastem among healthcare additions in Russell Microcap; Assertio, Sangamo removed
Russell 3000: Inovio, Ocugen among healthcare additions; Assertio, Ginkgo Bioworks among deletions
Analysts Are Bullish on These Healthcare Stocks: Assertio Therapeutics (ASRT), SurModics (SRDX)
Assertio Therapeutics Welcomes Brendan O’Grady as New CEO